Verrica Pharmaceuticals Inc. (VRCA) is a Healthcare stock trading at $4.84 (as of 2026-08-21), with a market capitalization of $83.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals develops and commercializes dermatology treatments in the United States, and it makes money primarily through product revenue from its therapies, supported by license and collaboration arrangements and potential milestone revenue from Torii Pharmaceutical.
The companys path to profitability hinges on whether commercial adoption translates into sustained growth in dispensed applicator units, while non-product items like Torii milestones and collaboration revenue can be helpful but are not a substitute for scalable product sales.
| Torii Milestones | $0.0B |
| Product Revenue | $0.0B |
| License and Collaboration Revenue | $0.0B |
Business quality (Weak): Key business drivers are present (product and dispensed-unit KPIs, plus Torii-related revenue). However, reported revenue is effectively zero in the latest quarter data provided, which limits how much you can infer from financial trends alone.
| Price | $4.84 |
| Market Cap | $83.15M |
| Price / Book | 5.18 |
| Price / Sales | 2.34 |
| FCF Yield | -43.0% |
| Revenue (TTM) | $35.58M |
| Net Margin | -50.3% |
| Revenue Growth (YoY) | 370.2% |
| EPS Growth (YoY) | 13.5% |
| FCF Growth (YoY) | -71.1% |
| Altman Z-Score | -6.86 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | Caligan Partners LP ($4.89M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jayson Rieger |
| Employees | 71 |
| Country | US |
| IPO Date | 2018-06-15 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.